Bill Text — Aug 14, 2012
This bill’s text is now available.
Aug 2, 2012
112th Congress, 2011–2013
This bill was introduced on August 2, 2012, in a previous session of Congress, but was not enacted.
Senator from Vermont
Read Text »
Last Updated: Aug 2, 2012
Length: 7 pages
A bill to eliminate requirements to undertake duplicative clinical testing of new pharmaceutical drugs, vaccines, biological products, or medical devices, when such duplication is inconsistent with relevant ethical norms.
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.
Referred to Committee
Last Action: Sep 29, 2010
The “S.” in “S. 3506” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The bill’s title was written by its sponsor.
The committee chair determines whether a bill will move past the committee stage.
There have been no votes related to this bill.
Search for similar bills.
Click a format for a citation suggestion:
Civic Impulse. (2015). S. 3506 — 112th Congress: Ethical Pathway Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s3506
“S. 3506 — 112th Congress: Ethical Pathway Act of 2012.” www.GovTrack.us. 2012. July 1, 2015 <https://www.govtrack.us/congress/bills/112/s3506>
|title=S. 3506 (112th)
|accessdate=July 1, 2015
|author=112th Congress (2012)
|date=August 2, 2012
|quote=Ethical Pathway Act of 2012